Mathilde Daubjerg

Mathilde smiling

Denmark

Meet Mathilde, who, at the age of 21, has been battling Lafora disease for half of her life.

Mathilde as a toddlerA Happy Childhood

Mathilde was a perfectly healthy and happy little girl, well-liked by everyone she met, and skilled academically. Outside of school, Mathilde was a Girl Scout. She loved animals, creative hobbies like drawing and painting, reading horror books, and watching Disney movies with her sisters.

Mathilde would help her neighbor by mowing their grass; she babysat children some afternoons. Her dream job, though, was to work in healthcare. She imagined a future living in a small yellow house with her own family. Mathide even daydreamed about her future children’s names: Agnes and Isaac.

No one ever imagines they will be diagnosed with a rare disease. Even as Mathilde’s first symptoms began, everyone thought she had epilepsy…

Mathilde’s First Symptoms

When Mathilde was around eight, she began having seizure activity. She dropped in her school yard and was unresponsive for more than an hour, but didn’t experience any jerking or cramping. The doctors recommended she have an EEG, the results of “which unfortunately disappeared in the system.” Life carried on for her.

Mathilde at ScoutsAlmost a year later, while participating in the Scouts program she loved, Mathilde had another episode where she was also uncontactable for over an hour. This time, she experienced muscle jerks in her right arm. She had another EEG, which showed epileptic activity around the same time as the results of the first one appeared.

Now in the third grade, Mathilde began to struggle with keeping up with school; she “suddenly had a hard time reading and spelling, which she had always been really good at.” Between her cognitive challenges, trouble controlling her body, and side effects of her medication, it became clear there was something more going on. Mathilde school portrait

She was admitted to the Epilepsy Hospital Filadelfia many times. Starting with GTK around age 10, Mathilde trialed many different medications and received different epilepsy diagnoses.

Lafora

In 2018, she began experiencing tics, muscle jerks, and dropping things. No medication helped her manage her body; her symptoms progressed. Once coordinated and active in Scouts, Mathilde was falling and experiencing undefined seizures frequently. Her whole body would twist, and she would hear her family, but she would be unable to answer them.

Mathilde age 21

Mathilde recently celebrated her 21st birthday.

The cycle of hospital visits and medications continued until Mathilde had a biopsy in 2020. As if March 2020 was not difficult enough, she was finally diagnosed with progressive myoclonus epilepsy. Her family learned their beloved Mathilde was fighting Lafora Body Disease and has been engaged with the community since.

While Mathilde’s age made her ineligible for the ION283 Safety Study, her loved ones remain hopeful that treatments will help her soon. She recently celebrated her 21st birthday on June 10.

Thank you to Mathilde’s mother, Jette, for sharing her daughter’s story with us.

Announcing June 18th ION283 Q&A: What’s Next?

Questions about the ION283 Safety Study or what’s next?  We hope you will join us for a Zoom ION283 Q&A next Wednesday, June 18th, at 4 p.m. ET.

Please register in advance to attend the meeting.

While we have our FAQs, a lot has changed over the past year. We are so thankful that members of the UTSW team will join us at the Q&A to share what they know. Please submit questions through this form by Monday, June 16th, for Dr. Minassian and Dr. Messahel to review them before the meeting.

Chart showing 6/10 patients enrolled in the ION283 safety study and 7/10 patients funded

Six patients have been enrolled in the ION283 Safety Study. We have funded the seventh participant and need to raise more for the final three children to join.

We will use Zoom’s closed caption translation feature. Please do not hesitate to join us in the ION283 Q&A or submit a question for us to ask if your first language is not English.

Chelsea’s Hope Advisory Board Meets to Discuss Research Goals

The Chelsea’s Hope Advisory Board met in April to provide guidance and support for the organization’s clinical and research goals in 2025:

  1. Get the ION283 safety study fully funded
  2. Assist with the analysis and publication of collected data in order to drive biomarker development for Lafora disease and determine global prevalence rates
  3. Establish Clinical Centers of Excellence and/or Guidelines for Clinicians

The primary topics of discussion were preparing for ION283 clinical trials, validating biomarkers for Lafora disease progression, and developing guidelines for seizure management for Lafora patients. 

ION283 Safety Study

The ION283 Safety Study now has six patients enrolled. Dr. Berge Minassian, who directs the study at the University of Texas Southwestern Medical Center, assured the board that patients will be enrolled as soon as funds are available. Also, Noventia is continuing its preparations to launch a clinical trial for ION283 in Europe. The timeline and details of this trial are still under discussion. Members of the Advisory Board will make themselves available to Noventia when requested to provide expertise and insight to ensure the best care for Lafora patients.

Four patients wait to join the ION283 Safety Study.

Biomarker Research Goals

Before any potential Lafora therapy can begin clinical trials to establish efficacy, biomarkers for Lafora disease progression must be identified and validated. Chelsea’s Hope and the broader Lafora community have assisted with global efforts to collect patient samples for biomarker analysis. The data from the two-year Natural History Study sponsored by Ionis is now ready for analysis. Members of the Advisory Board have committed to participate in working groups over the summer to review the data and recommend promising biomarkers.

Centers of Excellence

While our organization continues to support the development of therapies, there are steps that we can take now to improve the quality of patient care worldwide. This year, Chelsea’s Hope will sponsor a series of discussion panels to establish Centers of Excellence for Lafora Disease and guidelines for patient care. The Advisory Board recommended that the organization prioritize the development of guidelines for seizure management in Lafora disease. Dr. Roberto Michelucci will direct this effort with support from Chelsea’s Hope as well as a cohort of clinicians who treat Lafora patients.

Questions?

For more information about the Chelsea’s Hope Advisory Board,the projects, or the research goals outlined in this news post, please contact our Scientific and Executive Director, Dr. Kit Donohue (katherine@chelseashope.org). 

Announcing a Town Hall: Fully Funding the Safety Study

We hope you will join us for a Zoom Town Hall next Wednesday, May 21st, at 4 p.m. ET, to discuss fully funding the safety study. Register to attend today!

We have less than a month to fundraise to enroll the final four patients on the original timeline. Learn more about our fundraising initiatives and how you can get involved when you join our Town Hall next week.

Six out of 10 patients have been enrolled in the ION283 Safety Study.

We will use Zoom’s closed caption translation feature. Please do not hesitate to join us if your first language is not English.

Wondering about what’s next for ION283 development? Check our ION283 Safety Study FAQs and stay tuned for more information about a Q&A in June. We will not discuss that next week; we will focus on fundraising planning.